|
Real-time Estimate
Cboe BZX
21:07:57 04/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 40.44 USD | +0.05% |
|
-10.36% | -49.12% |
| 11-02 | Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target | RE |
| 10-22 | Wall Street, Please Make Up Your Mind on AI |  |
| Market Cap | 6.72B 5.99B 5.49B 4.99B 9.38B 635B 9.59B 65.61B 26.3B 336B 25.21B 24.67B 1,064B | P/E 2026 * |
-11.4x | P/E 2027 * | -20.7x |
|---|---|---|---|---|---|
| Enterprise Value | 6.61B 5.89B 5.41B 4.91B 9.23B 625B 9.45B 64.6B 25.9B 331B 24.83B 24.3B 1,048B | EV / Sales 2026 * |
7.17x | EV / Sales 2027 * | 4.99x |
| Free-Float |
99.06% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IONS | Delayed | |
CBOE
| IONS | Real-time | |
|
Tradegate
| ISI | Real-time | |
|
Boerse Muenchen
| ISI | Real-time | |
|
Mexican S.E.
| IONS * | End-of-day quote | |
|
Xetra
| ISI | Delayed | |
|
Deutsche Boerse AG
| ISI | Delayed | |
|
Börse Stuttgart
| ISI | Delayed | |
|
Borsa Italiana
| 1IONS | End-of-day quote |
Last Transcript: Ionis Pharmaceuticals, Inc.
| 1 day | -0.01% | ||
| 1 week | -10.36% | ||
| Current month | -7.51% | ||
| 1 month | -7.47% | ||
| 3 months | -26.91% | ||
| 6 months | -46.65% | ||
| Current year | -49.12% |
| 1 week | 39.33 |  | 45.84 |
| 1 month | 39.33 | | 45.84 |
| Current year | 39.33 | | 86.74 |
| 1 year | 39.33 | | 86.74 |
| 3 years | 23.95 | | 86.74 |
| 5 years | 23.95 | | 86.74 |
| 10 years | 23.95 | | 86.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/31/26 A | Others | Chief Technology Officer | 110 | 0.0001% | ||
| 8/31/26 A | Others | Executive/Senior Manager | 58 | 0.0000% | ||
| 8/31/26 A | Others | Founder | 98 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.05% | -10.36% | -44.77% | -13.05% | 6.72B | |
| +10.00% | +5.18% | +54.35% | +71.20% | 60.57B | |
| +1.44% | +5.05% | +22.52% | +99.64% | 55.51B | |
| +3.32% | +2.31% | +11.04% | +76.48% | 55.22B | |
| +1.57% | -4.71% | +26.04% | +34.02% | 43.27B | |
| +5.75% | +0.46% | +21.31% | +91.23% | 40.36B | |
| +1.98% | +5.16% | +238.83% | +821.33% | 41.63B | |
| -3.79% | -7.50% | +89.46% | +78.72% | 33.29B | |
| +5.32% | +6.04% | +20.27% | +52.98% | 32.27B | |
| +4.79% | +11.89% | -40.63% | +355.16% | 22.91B | |
| Average | +3.05% | +3.71% | +39.84% | +166.77% | 39.17B | |
| Weighted average by Cap. | +3.62% | +3.85% | +49.73% | +167.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 922M 822M 754M 685M 1.29B 87.17B 1.32B 9.01B 3.61B 46.14B 3.46B 3.39B 146B | 1.36B 1.21B 1.11B 1.01B 1.9B 129B 1.94B 13.28B 5.32B 68.02B 5.1B 5B 215B |
| Net income | -579M -516M -473M -430M -809M -54.75B -827M -5.66B -2.27B -28.98B -2.17B -2.13B -91.8B | -327M -292M -268M -243M -457M -30.94B -467M -3.2B -1.28B -16.37B -1.23B -1.2B -51.87B |
| Net Debt | -103M -91.77M -84.16M -76.49M -144M -9.73B -147M -1.01B -403M -5.15B -387M -378M -16.32B | 68.31M 60.87M 55.82M 50.73M 95.36M 6.46B 97.54M 667M 267M 3.42B 256M 251M 10.82B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/11/26 | $40.34 | -0.20% | 1,305,400 |
| 03/11/26 | $40.42 | -1.99% | 4,006,909 |
| 02/11/26 | $41.24 | -5.24% | 2,559,959 |
| 30/10/26 | $43.52 | -1.96% | 1,522,192 |
| 29/10/26 | $44.39 | -1.14% | 1,833,848 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IONS Stock
Select your edition
All financial news and data tailored to specific country editions
